Drugs / Ifupinostat
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07676175 | Jul 2026 → Jan 2028 expected | peripheral T-cell lymphoma, not otherwise specified | BeBetter Med Inc | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06792253 | Jan 2025 → Dec 2028 expected | relapsed/refractory diffuse large B-cell lymphoma | BeBetter Med Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ifupinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07676175 ↗ |
| Route | Intravenous | “Administered by intravenous infusion at a dose of 8.2 mg/m² or 18.5 mg/m².” NCT07676175 ↗ |